

1. Record Nr.	UNINA9910810864103321
Titolo	Description and analysis of the VA National Formulary // David Blumenthal and Roger Herdman, editors ; VA Pharmacy Formulary Analysis Committee, Division of Health Care Services, Institute of Medicine
Pubbl/distr/stampa	Washington, D.C., : National Academy Press, c2000
ISBN	0-309-18353-7 1-280-18551-1 9786610185511 0-309-56964-8
Edizione	[1st ed.]
Descrizione fisica	xvi, 262 pages : illustrations
Altri autori (Persone)	BlumenthalDavid <1948-> HerdmanRoger
Soggetti	Drugs - United States Drug utilization - Government policy - United States Medicine Veterans - Medical care - United States - Quality control
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references (p. 201-216).
Nota di contenuto	DESCRIPTION AND ANALYSIS OF THE VA National Formulary -- Copyright -- Preface -- REVIEWERS -- Contents -- Executive Summary -- SUMMARY AND CONCLUSIONS -- Restrictiveness -- Cost -- Quality -- Comparisons -- Recommendations -- 1 Introduction -- LEGISLATIVE AND EXECUTIVE BRANCH HISTORY -- History of the IOM Study -- The IOM Committee -- FORMULARIES AND FORMULARY SYSTEMS: HISTORY AND DEFINITIONS -- Modern Formularies and Formulary Systems -- Economic Focus of Formularies -- Types of Formularies and Their Restrictiveness -- Formulary Control -- GENERIC SUBSTITUTION -- THERAPEUTIC INTERCHANGE -- LOCAL VA FACILITY AND VISN FORMULARIES AND THE NATIONAL FORMULARY -- History of VA Formulary Management Prior to the National Formulary -- Reorganization of the VA -- Impact of the VA Fixed Budget -- Establishing the VA National Formulary -- Evolution of the National

Formulary -- Medical Staff Input -- National Formulary Classes --
Formulary Relationship to Pharmaceutical Companies -- REPORT
OUTLINE -- 2 Is the VA National Formulary Overly Restrictive and Does
It Prevent Physicians from Meeting the Health Care Needs of... --
BACKGROUND -- Elements of Restrictiveness -- SIZE AND COVERAGE
OF THE NATIONAL FORMULARY -- Adequacy of the VA National
Formulary -- Closed and Preferred Drug Classes in the VA --
Restrictiveness of Class Closure -- Excluded Drugs and Other Limits --
National Formulary Effects on Drug Use -- ADDITION OF NEW DRUGS
AND FORMULARY REAPPRAISAL -- National Policy Regarding New Drugs
-- VISN Addition of New FDA Approvals -- Evaluation of the VA Process
for Adding New FDA-Approved Priority Drugs -- Addition of Existing
Drugs by the VA -- Addition of Newly Approved or Existing Drugs in
Other Health Care Systems -- THE NONFORMULARY PROCESS --
THERAPEUTIC INTERCHANGE -- OTC DRUG COVERAGE, GENERIC
SUBSTITUTION, AND PHYSICIAN SATISFACTION.
Generic Substitution -- Veterans' Complaints -- VA Physician
Satisfaction -- SUMMARY -- 3 What Are the Potential Costs to VA
Health Care Associated with the National Formulary for Drugs? --
INTRODUCTION -- THE VHA NATIONAL FORMULARY AS IT AFFECTS
COSTS -- Background -- Basic Economics of the VA National Formulary
-- Features of the National Formulary -- VISN Implementation Issues
-- Other Influences on VHA Pharmaceutical Spending -- ANALYTICAL
FRAMEWORK -- DATA -- EMPIRICAL METHODS -- RESULTS OF THE IOM
COMMITTEE ANALYSIS OF COST EFFECTS -- How Have the VHA and the
Veteran User Population Changed During the Study Period? -- How Has
the National Formulary Affected Prices for Closed and Preferred
Classes? -- How Has the National Formulary Affected Prescribing
Patterns Within the Closed and Preferred Classes? -- How Has the
National Formulary Affected Pharmaceutical Spending per Veteran User
for Closed and Preferred Classes? -- IS THERE EVIDENCE THAT
CHANGES IN FORMULARY POLICY HAVE RESULTED IN INCREASED
UTILIZATION ELSEWHERE IN THE VHA SYSTEM? -- Exploration of
Changes in Hospital Discharges per VHA User -- COSTS ASSOCIATED
WITH IMPLEMENTING AND MANAGING THE NATIONAL FORMULARY --
Estimated National Formulary Savings -- CONCLUSIONS -- 4 What Are
the Effects of the National Formulary and Related Policies on Quality of
Care? -- BACKGROUND INFORMATION -- Sources of Quality Data --
QUALITY OF CARE IN THE VHA AND EFFECTS OF THE NATIONAL
FORMULARY -- PHARMACY, CLINICAL, AND FORMULARY PROGRAM
ELEMENTS RELEVANT TO QUALITY OF CARE -- Clinical Pharmacy --
P&T COMMITTEES -- THE VA PBM COMPLEX -- Additions to,
and Quality of, the National Formulary -- POLICIES AND PROCEDURES
-- Drug Class Reviews -- Clinical Guidelines and Drug Utilization
Reviews -- The Nonformulary Process -- Therapeutic Interchange,
Policy, and Results.
EFFECTS OF THE NATIONAL FORMULARY ON USE OF DRUGS BY THE VA
-- ADVERSE DRUG EVENTS -- Changes in Inpatient Hospital Discharges
Associated with the National Formulary -- PATIENT COMPLAINTS-
ADVOCATE, VETERANS OF FOREIGN WARS, AND SURVEY DATA --
PHYSICIAN COMPLAINTS AND SURVEY DATA -- SUMMARY STATEMENT
-- 5 How Does the VA National Formulary Compare with Private
Insurance Formularies for Drugs and Devices and with Other... --
INTRODUCTION -- IMPLEMENTATION OF DRUG MANAGEMENT
STRATEGIES IN MANAGED CARE -- IMPACT OF STATE LEGISLATION ON
MCO PRACTICE -- PUBLIC-SECTOR PROGRAMS -- Medicaid -- Medicaid
Fee for Service -- Medicaid Prescription Drug Benefit -- Medicaid
Controls Prior Approval and Formulary Systems -- Comparison to the

VA -- Effects of Medicaid Formularies and Formulary Systems -- Effects of Medicaid Prior Approval Systems -- Effects of Medicaid Prescription Limits -- Medicaid Managed Care: Background -- Drug Benefit in Medicaid Managed Care -- DEPARTMENT OF DEFENSE -- Health Care System and Pharmacy Benefit -- DOD Formulary and Formulary System -- GENERAL COMMENTS ON COMPARISONS -- 6 The VA National Formulary and Veterans Health Care -- INTRODUCTION -- BACKGROUND AND CONTEXT -- THE VETERANS HEALTH ADMINISTRATION -- RESTRICTIVENESS -- COSTS -- QUALITY -- COMPARISONS -- References -- Acronyms -- APPENDIX A Interim Report of the Committee on VA Pharmacy Formulary Analysis to the Department of Veterans Affairs and the... -- JANUARY 28, 2000 -- APPENDIX B Academy of Managed Care Pharmacy's Managed Care Formulary and Pharmacy Benefit Design Survey -- AMCP MANAGED CARE FORMULARY AND PHARMACY BENEFIT DESIGN SURVEY (JANUARY 2000) -- The P&T Committee -- Exclusion of Coverage -- Closed Formularies -- Open-Preferred Formularies -- Open-Passive Formularies -- Other Types of Formularies -- Drug Restrictions -- Generic Drugs. Access to Nonformulary Drugs -- Cost-Containment Measures -- Addition of New FDA-Approved Drugs -- Appeals Process -- Continuation of Care -- APPENDIX C Additional Cost Information -- APPENDIX D Glossary -- APPENDIX E Drug Classes and Drug Index -- DRUG CLASSES -- OTHER DRUGS -- Committee Biographies.
